Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin GB0009895292
Ticker AZN
Company ASTRAZENECA
Currency $
Price
Aware Investor Index (AII) 81.5628
Recommendation STRONG BUY
P/E 9.48
ROE 29.38 %
Capitalization 46,346,860,000 $
Dividend Yield 7.65 %
P/S 2.30
AII Position 38
P/E Position 57
ROE Position 92
Capitalization Position 190
Dividend Yield Position 31
Sales 20,152,000,000 $
10-Year Average Earnings 4,888,800,000 $
Shares Outstanding 1,267,000,000
Equity 16,642,000,000 $
Dividend per Share 2.8 $
Industry Pharmaceutical
Country Great Britain
ASTRAZENECA Investor Relations Web Site http://www.astrazeneca.com/Investors







Sales:

YEAR MONTH AMOUNT
2017 12 20,152,000,000.00 $
2016 12 21,319,000,000.00 $
2015 12 23,641,000,000.00 $
2014 12 26,095,000,000.00 $
2013 12 25,711,000,000.00 $
2012 12 27,973,000,000.00 $
2011 12 33,591,000,000.00 $
2010 12 33,269,000,000.00 $
2009 12 32,804,000,000.00 $
2008 12 31,601,000,000.00 $

Earnings:

YEAR MONTH AMOUNT
2017 12 2,868,000,000.00 $
2016 12 3,406,000,000.00 $
2015 12 2,826,000,000.00 $
2014 12 -271,000,000.00 $
2013 12 2,458,000,000.00 $
2012 12 6,405,000,000.00 $
2011 12 9,470,000,000.00 $
2010 12 8,106,000,000.00 $
2009 12 7,490,000,000.00 $
2008 12 6,130,000,000.00 $

Equity:

YEAR MONTH AMOUNT
2017 12 16,642,000,000.00 $
2016 12 16,669,000,000.00 $
2015 12 18,509,000,000.00 $
2014 12 19,646,000,000.00 $
2013 12 23,253,000,000.00 $
2012 12 23,952,000,000.00 $
2011 12 23,472,000,000.00 $
2010 12 23,410,000,000.00 $
2009 12 20,821,000,000.00 $
2008 12 16,060,000,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2017 12 1,267,000,000
2016 12 1,266,000,000
2015 12 1,265,000,000
2014 12 1,264,000,000
2013 12 1,254,000,000
2012 12 1,261,000,000
2011 12 1,367,000,000
2010 12 1,446,000,000
2009 12 1,450,000,000
2008 12 1,453,000,000

 












Bloomberg News for ASTRAZENECA:



Google News for ASTRAZENECA:

Nasdaq - 1 day ago
Strength Seen in AstraZeneca (AZN): Stock Soars 9.3%
AstraZeneca PLC AZN was a big mover last session, as the company saw its shares rise more than 9% on the day. The move came on solid ...
Fairfield Current
AstraZeneca's (AZN) Q4 Earnings Beat, New Drugs Drive Sales
AstraZeneca plc AZN beat the Zacks Consensus Estimate for both earnings and sales in the fourth quarter of 2018. Pascal Soriot ...
BharataPress
AstraZeneca declares $1.90 dividend
AstraZeneca (NYSE:AZN) declares second interim dividend of $1.90/share, bringing total annual dividend to $2.80, unchanged from the prior ...
PressOracle
AstraZeneca Q4 2018 Earnings Preview
AstraZeneca (NYSE:AZN) is scheduled to announce Q4 earnings ... Over the last 2 years, AZN has beaten EPS estimates 100% of the time and ...
Nasdaq - 2 days ago
AstraZeneca (AZN) Given a GBX 7100 Price Target at JPMorgan ...
JPMorgan Chase & Co. set a GBX 7,100 ($92.77) target price on AstraZeneca (LON:AZN) in a research note released on Thursday morning.
Investorplace.com
Franklin Resources Boosted Its Astrazeneca Plc (AZN) Stake by ...
Franklin Resources Inc increased its stake in Astrazeneca Plc (AZN) by 130.66% based on its latest 2018Q3 regulatory filing with the SEC.
Motley Fool UK
AstraZeneca shakes up R&D
Aimed at boosting the efficiency of its R&D organization, AstraZeneca (NYSE:AZN) chief Pascal Soriot has streamlined the group into two ...
Wall Street Journal
AstraZeneca +6% after Q4 beat
AstraZeneca (AZN) Q4 results: Revenues: $6,417M (+11.1%); Product Sales: $5,768M (+5.1%); Externalisation Revenue: $649M (+123.8%).
Seeking Alpha - 2 days ago
Astrazeneca Plc (AZN) MFI Reading Under the Microscope
Astrazeneca Plc (AZN) shares have seen the Money Flow Indicator climb above 60, potentially spelling a near-term reversal if it crosses above ...
Seeking Alpha - 2 days ago
Technically Speaking For February 14: AstraZeneca PLC (AZN ...
AstraZeneca PLC (AZN) sank -0.79% this week, a trend that has led to both investors and traders taking note of the stock. Over the past one ...


Back